Biofabricated Muscle Repair: Mechanisms, Clinical Applications, and Future Directions

Abstract

Biofabricated muscle repair represents a rapidly evolving field in regenerative medicine, leveraging tissue engineering, biomaterials, and cellular therapies to restore function in damaged or diseased skeletal muscle. This review synthesizes current evidence from preclinical and clinical studies, highlighting epidemiological trends, underlying pathophysiological mechanisms, risk factors, clinical presentation, diagnostic modalities, conventional and advanced management strategies, as well as guideline recommendations. Special emphasis is placed on the translation of laboratory advances into clinical practice, recent breakthroughs in biofabrication technologies, and the future scope for personalized muscle regeneration.

Introduction

Muscle injuries pose a significant clinical challenge due to the limited regenerative capacity of adult skeletal muscle, particularly in cases of volumetric muscle loss (VML) arising from trauma, tumor ablation, or degenerative diseases. Traditional management options, such as autologous tissue transfer, often result in suboptimal functional outcomes and donor site morbidity. Biofabricated muscle repair aims to address these limitations through the integration of scaffold-based and scaffold-free approaches, stem cell biology, and bioactive cues to engineer functional muscle constructs. This review provides a comprehensive, evidence-based overview for healthcare professionals on the state-of-the-art and future prospects of biofabricated muscle repair.

Epidemiology / Disease Burden

Skeletal muscle injuries are prevalent in both civilian and military populations, with an estimated incidence of 10-55% in sports-related trauma and up to 40% of extremity injuries in combat scenarios involving VML. Muscle loss also complicates oncological resections, chronic infections, and degenerative myopathies. The global burden is substantial, contributing to long-term disability, reduced quality of life, and increased healthcare expenditure. Epidemiological studies underscore the unmet need for effective regenerative strategies, especially as the population ages and the prevalence of chronic diseases rises.

Pathophysiology

Muscle regeneration involves a coordinated sequence of events, including inflammation, activation of satellite cells, proliferation, differentiation, and remodeling. However, in VML and certain myopathies, this regenerative process is overwhelmed, leading to fibrosis and loss of contractile tissue. Key molecular mechanisms include upregulation of myogenic regulatory factors (Myf5, MyoD), impaired satellite cell niche, dysregulated extracellular matrix remodeling, and chronic inflammatory signaling. Biofabrication seeks to recapitulate the native muscle microenvironment, providing structural, biochemical, and mechanical cues necessary for effective myogenesis and functional integration.

Risk Factors

Risk factors for impaired muscle repair include advanced age, diabetes mellitus, peripheral vascular disease, chronic corticosteroid use, and genetic myopathies. Lifestyle factors such as poor nutrition, smoking, and sedentary behavior further compromise regenerative capacity. In the context of trauma, the extent of tissue loss, contamination, and associated vascular or nerve injury are critical determinants of repair outcomes. Recognizing these risk factors is essential for patient stratification and tailoring biofabricated therapies.

Clinical Features

Patients with significant muscle loss typically present with localized swelling, weakness, deformity, and functional impairment. In VML, there may be visible soft tissue defects, persistent pain, and instability of the affected limb. Chronic cases are characterized by atrophy, contracture, and secondary complications such as joint dysfunction. Detailed clinical assessment, including objective strength testing and functional scores, is crucial for baseline evaluation and monitoring therapeutic response.

Diagnosis

Diagnosis of muscle defects relies on a combination of clinical examination and advanced imaging modalities. MRI is the gold standard for delineating muscle architecture, extent of tissue loss, and fibrosis. Ultrasound offers real-time assessment of muscle integrity and vascularity, while CT provides detailed anatomical mapping in complex cases. Molecular and histopathological analyses can further characterize the injury environment and guide regenerative strategies. Biomarkers of inflammation and myogenesis are under investigation for dynamic monitoring of tissue repair.

Treatment & Management

Conventional management includes physical rehabilitation, pharmacologic modulation of inflammation, and surgical interventions such as autografts, allografts, or muscle flaps. However, these approaches are limited by donor site morbidity, immune rejection, and suboptimal functional recovery. Biofabricated muscle constructs, composed of biocompatible scaffolds seeded with autologous or allogeneic myogenic cells, offer a promising alternative. These constructs can be engineered to match patient-specific defect geometry and are increasingly being evaluated in preclinical and early-phase clinical trials for their ability to restore muscle mass and function.

Recent Advances / Emerging Therapies

Recent advances in biofabrication include 3D bioprinting, decellularized extracellular matrix scaffolds, and the use of induced pluripotent stem cells (iPSCs) for generating patient-specific myogenic progenitors. Technologies such as microfluidics and bioactive hydrogels enable spatially controlled delivery of growth factors and cells, enhancing vascularization and integration with host tissue. Gene editing and synthetic biology approaches are being explored to enhance myogenic potential and modulate the inflammatory milieu. Early clinical studies demonstrate safety and functional improvement, though challenges remain in scaling, vascularization, and innervation of large constructs.

Guideline Recommendations

Current guidelines emphasize a multidisciplinary approach to muscle repair, integrating surgical, rehabilitative, and regenerative strategies. While biofabricated constructs are not yet standard of care, they are recommended for consideration in clinical trials or compassionate use settings for patients with large, non-healing muscle defects. Consensus statements highlight the need for standardized protocols, robust clinical endpoints, and long-term safety monitoring. Ongoing research is expected to inform future guidelines and accelerate clinical translation.

Conclusion

Biofabricated muscle repair is poised to transform the management of complex muscle injuries and myopathies. By leveraging advances in tissue engineering, stem cell biology, and biomaterials science, these approaches offer the potential for personalized, functionally integrated muscle regeneration. Continued research, interdisciplinary collaboration, and rigorous clinical evaluation will be essential to overcome current limitations and realize the full therapeutic potential of biofabricated muscle constructs in routine clinical practice.